Two global haemostatic assays as additional tools to monitor treatment in cases of haemophilia A

Thrombosis and Haemostasis

Volumn 108, Issue 1, 2012, Pages 21-31

  Antovic, Jovan P ^a   Mikovic, Danijela ^b   Elezovic, Ivo ^c   Holmström, Margareta ^a   Wilkens, Matthias ^d   Elfvinge, Petra ^a   Soutari, Nida Mahmoud Hourani ^a   Antovic, Aleksandra ^e  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Blood Transfusion Institute of Serbia   (Serbia)

^c UNIVERSITY OF BELGRADE   (Serbia)

^d Siemens Healthcare Diagnostics Products GmbH   (Germany)

^e DANDERYD HOSPITAL   (Sweden)

Author keywords

Endogenous thrombin potential (ETP); Factor VIII (FVIII); Haemophilia a; On demand treatment; Overall haemostatic potential (OHP); Prophylactic treatment

Indexed keywords

BLOOD CLOTTING FACTOR 8; FIBRIN; RECOMBINANT BLOOD CLOTTING FACTOR 8; THROMBIN;

ADOLESCENT; ADULT; AGED; ARTICLE; ASSAY; BLEEDING; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE SEVERITY; ENDOGENOUS THROMBIN POTENTIAL ASSAY; HEMOPHILIA A; HEMOSTASIS; HUMAN; MAJOR CLINICAL STUDY; OVERALL HAEMOSTATIC POTENTIAL ASSAY; PATIENT MONITORING; PRIORITY JOURNAL; SINGLE DRUG DOSE; TREATMENT RESPONSE;

ADULT; AGED; BLOOD COAGULATION TESTS; DISEASE PROGRESSION; DRUG MONITORING; FACTOR VIII; FEMALE; HEMOPHILIA A; HEMOSTASIS; HUMANS; MALE; MIDDLE AGED; THROMBIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84863643583     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH11-11-0811     Document Type: Article

References (26)

1. Nilsson IM, Berntorp E, Löfqvist T, et al. Twenty-five years experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32.
2. Blanchette VS, Manco-Johnson M, Santagostino E, et al. Optimizing factor prophylaxis for the haemophilia population: where do we stand? Haemophilia 2004; 10 (Suppl 4): 97-104.
3. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe haemophilia. N Engl J Med 2007; 357: 535-544.
4. Rainsford SG, Hall A. A three-year study of adolescent boys suffering from haemophilia and allied disorders. Br J Haematol 1973; 24: 539-551.
5. Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994; 236: 391-399.
6. van den Berg HM, Fischer K, Mauser-Bunschoten EP, et al. Long-term outcome of individualized prophylactic treatment of children with severe haemophilia. Br J Haematol 2001; 112: 561-565.
7. Feldman BM, Pai M, Rivard GE, et al. Association of Haemophilia Clinic Directors of Canada Prophylaxis Study Group. Tailored prophylaxis in severe haemophilia A: interim results from the first 5 years of the Canadian Haemophilia Primary Prophylaxis Study. J Thromb Haemost 2006; 4: 1228-1236.
8. Wielders S, Mukherjee M, Michiels J, et al. The routine determination of the endogenous thrombin potential, first results in different forms of hyper- and hypocoagulability. Thromb Haemost 1997; 77: 629-636.
9. Keularts IM, Hamulyak K, Hemker HC, et al. The effect of DDAVP infusion on thrombin generation in platelet rich plasma of von Willebrand type 1 and mild haemophilia A patients. Thromb Haemost 2000; 84: 638-642.
10. Kawaguchi C, Takahashi Y, Hanesaka Y, et al. The in vitro analysis of the coagulation mechanism of activated factor VII using thromboelastogram. Thromb Haemost 2002; 88: 768-772.
11. Beltrán-Miranda CP, Khan A, Jaloma-Cruz AR, et al. Thrombin generation and phenotypic correlation in haemophilia A. Haemophilia 2005; 11: 326-334.
12. Dargaud Y, Béguin S, Lienhart A, et al. Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb Haemost 2005; 93: 475-480.
13. Sorensen B, Ingerslev J. Tailoring haemostatic treatment to patient requirements - an update on monitoring haemostatic response using thrombelastography. Haemophilia 2005; 11 (Suppl 1): 1-6.
14. Hvas AM, Sorensen HT, Norengaard L, et al. Tranexamic acid combined with recombinant factor VIII increases clot resistance to accelerated fibrinolysis in severe haemophilia A J Thromb Haemost 2007; 5: 2408-2414.
15. Goldenberg NA, Hathaway WE, Jacobson L, et al. Influence of factor VIII on overall coagulability and fibrinolytic potential of haemophilic plasma as measured by global assay: monitoring in haemophilia A. Haemophilia 2006; 12: 605-614.
16. Livnat T, Martinowitz U, Zivelin A, et al. A highly sensitive thrombin generation assay for assessment of recombinant activated factor VII therapy in haemophilia patients with an inhibitor. Thromb Haemost 2011; 105: 688-695.
17. He S, Antovic A, Blombäck M. A simple and rapid laboratory method for determination of haemostasis potential in plasma II. Modifications for use in routine laboratories and research work. Thromb Res 2001; 103: 355-361.
18. Antovic A, Blombäck M, Sten-Linder M, et al. Identifying hypocoagulable states with a modified global assay of overall haemostasis potential in plasma. Blood Coagul Fibrinolysis 2005; 16: 585-596.
19. Berntrop E, Björkman S. The pharmacokinetics of clotting factor therapy. Haemophilia 2003; 9: 353-359.
20. Salvagno GL, Astermark J, Lippi G, et al. Thrombin generation assay: a useful routine check-up tool in the management of patients with haemophilia? Haemophilia 2009; 15: 290-296.
21. Ghosh K, Shetty S, Mohanty D. Milder clinical presentation of haemophilia A with severe deficiency of factor VIII as measured by one-stage assay. Haemophilia 2001; 7: 9-12.
22. Antovic A, Blombäck M, Bremme K, et al. Increased haemostasis potential persists in women with previous thromboembolism with or without APC resistance. J Thromb Haemost 2003; 1: 2531-2535.
23. Varki A. Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood 2007; 110: 1723-1729.
24. Biere-Rafi S, Tuinenburg A, Haak BW, et al. Factor VIII deficiency does not protect against atherosclerosis. J Thromb Haemost 2012; 10: 30-37.
25. Tuinenburg A, Rutten A, Kavousi M, et al. Coronary artery calcification in haemophilia A: No evidence for a protective effect of factor VIII deficiency on atherosclerosis. Arterioscler Thromb Vasc Biol 2012; 32: 799-804.
26. Biere-Rafi S, Baarslag MA, Peters M, et al. Cardiovascular risk assessment in haemophilia patients. Thromb Haemost 2011; 105: 274-278.